Christopher Tovey - GW Pharmaceuticals COO, Executive Director

Director

Mr. Christopher John Tovey is Chief Operating Officer, Executive Director of GW Pharmaceuticals PLC. Mr. Tovey has over 25 years experience in the pharmaceutical industry. Prior to joining our Company, Mr. Tovey was at UCB Pharmaceuticals from 2006 to 2012. Most recently, Mr. Tovey was the Vice President of Global Marketing Operations where he was responsible for worldwide marketing activities on a portfolio of UCB products generating over 2.0 billion in annual sales. Previous experience and roles at UCB included Managing Director Greece and Cyprus, and leader of all UCB activities on the orphan narcotic medication Xyrem, used in the treatment of narcolepsy. Mr. Tovey previously spent 18 years at GlaxoSmithKline plc in senior commercial roles in both the European and U.K. organizations. These roles included Director Commercial Strategy Distribution Europe, Director European Vaccine Therapy Director Commercial Development U.K., Director Vaccines Business Unit U.K. and Business Unit Manager Oncology U.K. While at GSK, Mr. Tovey worked across a wide range of therapeutic areas including infectious diseases, neurology, oncology, diabetes, respiratory, and immunology. since 2012.
Age 48
Tenure 12 years
Phone(44) 1223 235667
Webwww.gwpharm.com

GW Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (3.55) % which means that it has lost $3.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.92) %, meaning that it created substantial loss on money invested by shareholders. GW Pharmaceuticals' management efficiency ratios could be used to measure how well GW Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 43.64 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GW Pharmaceuticals Plc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist GW Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, GW Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GW Pharmaceuticals Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GWPH to invest in growth at high rates of return. When we think about GW Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Samuel ScottBank Of New
75
John HinshawBank Of New
48
Loudon OwenAcademy Sports OutdoorsInc
N/A
Karin IretonAcademy Sports OutdoorsInc
59
James WilliamsMarine Products
85
Steven BlackBank Of New
65
Jeffrey GoldsteinBank Of New
65
Wesley SchackBank Of New
70
Pamela RollinsMarine Products
63
Elizabeth RobinsonBank Of New
52
Mark NordenbergBank Of New
68
Larry PrinceMarine Products
78
Timothy RollinsMarine Products
58
Chang ChanIntegrated Media Technology
50
William RichardsonBank Of New
73
Edmund KellyBank Of New
74
Linda CookBank Of New
62
Jennifer MorganBank Of New
48
Harry CynkusMarine Products
70
Linda GrahamMarine Products
78
john LukeBank Of New
68
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom. Gw Pharma operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 1161 people. GW Pharmaceuticals Plc (GWPH) is traded on NASDAQ Exchange in USA and employs 1,161 people.

Management Performance

GW Pharmaceuticals Plc Leadership Team

Elected by the shareholders, the GW Pharmaceuticals' board of directors comprises two types of representatives: GW Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GWPH. The board's role is to monitor GW Pharmaceuticals' management team and ensure that shareholders' interests are well served. GW Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GW Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
William Waldegrave, Non-Executive Independent Director
Christopher Tovey, COO, Executive Director
Thomas Lynch, Non-Executive Independent Director
Catherine Mackey, Non-Executive Independent Director
Justin Gover, CEO, Director
Geoffrey Guy, Executive Chairman of the Board
James Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
Julian Gangolli, Executive Director
Alicia Secor, Non-Executive Independent Director
Adam George, CFO, Company Secretary, Director
Cabot Brown, Non-Executive Independent Director
Stephen Wright, Research & Development Director, Executive Director
Darren Cline, Chief Commercial Officer, U.S.

GWPH Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GW Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Consideration for investing in GWPH Stock

If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Transaction History
View history of all your transactions and understand their impact on performance
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities